Incorporating clinical outcomes and economic consequences into drug formulary decisions: A practical approach

American Journal of Managed Care

Volumn 5, Issue 3, 1999, Pages 277-285

  Mather, Dell B ^a   Sullivan, Sean D ^a   Augenstein, Darren ^a   Fullerton, D S Pete ^a   Atherly, Debbie ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Regence BlueShield   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NEW DRUG;

ARTICLE; CLINICAL PHARMACY; DRUG FORMULARY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; HEALTH CARE PLANNING; HEALTH ECONOMICS; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BLUE SHIELD; DATA COLLECTION; DECISION MAKING; DRUG COSTS; FORMULARIES; GUIDELINES; MANAGED CARE PROGRAMS; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); TRUTH DISCLOSURE; WASHINGTON;

EID: 0033064813     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Langley PC, Sullivan SD. Pharmacoeconomic evaluations: Guidelines for drug purchasers. J Managed Care Pharm 1996;2:671-677.
2. Mather DB, Sullivan SD. The role of pharmacoeconomic data in formulary decisions. Pharmaceutical News 1998;5:11-15.
3. Henry D. Economic analysis as an aid to subsidisation decisions: The development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992;1:54-67.
4. Detsky AS. Guidelines for economic analysis of pharmaceutical products: A draft document for Ontario and Canada. PharmacoEconomics 1993;3:354-361.
5. Shornick JK. Drug therapy policy at Group Health Cooperative of Puget Sound. Drug Benefit Trends 1997;9(12):23-26,42.
6. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992;268:2420-2425.
7. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991;324:1362-1365.
8. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med 1992;116:238-244.
9. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994;331:669-670.
10. Agro KE, Bradley CA, Mittmann N, et al. Sensitivity analysis in health economic and pharmacoeconomic studies: An appraisal of the literature. PharmacoEconomics 1997;11:75-88.
11. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. Br Med J 1996;313:275-283.
12. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
13. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: A report on principles. Ann Intern Med 1995;123:60-69.
14. Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Soc Sci Med 1997;45:511-521.